These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 19009265)

  • 1. Selection and characterization of drug-resistant HCV replicons in vitro with a flow cytometry-based assay.
    Robotham JM; Nelson HB; Tang H
    Methods Mol Biol; 2009; 510():227-42. PubMed ID: 19009265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).
    Flint M; Mullen S; Deatly AM; Chen W; Miller LZ; Ralston R; Broom C; Emini EA; Howe AY
    Antimicrob Agents Chemother; 2009 Feb; 53(2):401-11. PubMed ID: 18936191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro.
    Robida JM; Nelson HB; Liu Z; Tang H
    J Virol; 2007 Jun; 81(11):5829-40. PubMed ID: 17376913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro.
    Yang F; Robotham JM; Nelson HB; Irsigler A; Kenworthy R; Tang H
    J Virol; 2008 Jun; 82(11):5269-78. PubMed ID: 18385230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a novel dicistronic reporter-selectable hepatitis C virus replicon suitable for high-throughput inhibitor screening.
    Hao W; Herlihy KJ; Zhang NJ; Fuhrman SA; Doan C; Patick AK; Duggal R
    Antimicrob Agents Chemother; 2007 Jan; 51(1):95-102. PubMed ID: 17060518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells.
    Yon C; Viswanathan P; Rossignol JF; Korba B
    Antiviral Res; 2011 Sep; 91(3):233-40. PubMed ID: 21703309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tricistronic hepatitis C virus subgenomic replicon expressing double transgenes.
    Cheng X; Gao XC; Wang JP; Yang XY; Wang Y; Li BS; Kang FB; Li HJ; Nan YM; Sun DX
    World J Gastroenterol; 2014 Dec; 20(48):18284-95. PubMed ID: 25561795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach.
    Yang F; Robotham JM; Grise H; Frausto S; Madan V; Zayas M; Bartenschlager R; Robinson M; Greenstein AE; Nag A; Logan TM; Bienkiewicz E; Tang H
    PLoS Pathog; 2010 Sep; 6(9):e1001118. PubMed ID: 20886100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV genotype 1b chimeric replicon with NS5B of JFH-1 exhibited resistance to cyclosporine A.
    Abe K; Ikeda M; Ariumi Y; Dansako H; Wakita T; Kato N
    Arch Virol; 2009; 154(10):1671-7. PubMed ID: 19779801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
    Puyang X; Poulin DL; Mathy JE; Anderson LJ; Ma S; Fang Z; Zhu S; Lin K; Fujimoto R; Compton T; Wiedmann B
    Antimicrob Agents Chemother; 2010 May; 54(5):1981-7. PubMed ID: 20176894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV replicons: overview and basic protocols.
    Lohmann V
    Methods Mol Biol; 2009; 510():145-63. PubMed ID: 19009259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominant negative effect of wild-type NS5A on NS5A-adapted subgenomic hepatitis C virus RNA replicon.
    Graziani R; Paonessa G
    J Gen Virol; 2004 Jul; 85(Pt 7):1867-1875. PubMed ID: 15218171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
    Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zebrafish as a potential model organism for drug test against hepatitis C virus.
    Ding CB; Zhang JP; Zhao Y; Peng ZG; Song DQ; Jiang JD
    PLoS One; 2011; 6(8):e22921. PubMed ID: 21857967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
    Ivanisenko NV; Mishchenko EL; Akberdin IR; Demenkov PS; Likhoshvai VA; Kozlov KN; Todorov DI; Gursky VV; Samsonova MG; Samsonov AM; Clausznitzer D; Kaderali L; Kolchanov NA; Ivanisenko VA
    PLoS One; 2014; 9(3):e91502. PubMed ID: 24643004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.